CoChat

Neuromodulators for pain management in rheumatoid arthritis

Open access
Richards, Bethan L, Whittle, Samuel L, Buchbinder, Rachelle · 2012 · Cochrane Database of Systematic Reviews
Cited by 100

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Pain management is a high priority for patients with rheumatoid arthritis (RA). Despite deficiencies in research data, neuromodulators have gained widespread clinical acceptance as adjuvants in the management of patients with chronic musculoskeletal pain. OBJECTIVES: The aim of this review was to determine the efficacy and safety of neuromodulators in pain management in patients with RA. Neuromodulators included in this review were anticonvulsants (gabapentin, pregabalin, phenytoin, sodium valproate, lamotrigine, carbamazepine, levetiracetam, oxcarbazepine, tiagabine and topiramate), ketamine, bupropion, methylphenidate, nefopam, capsaicin and the cannabinoids. SEARCH METHODS: We performed a computer-assisted search of the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, 4th quarter), MEDLINE (1950 to week 1 November 2010), EMBASE (Week 44, 2010) and PsycINFO (1806 to week 2 November 2010). We also searched the 2008 and 2009 American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) conference abstracts and performed a handsearch of reference lists of articles. SELECTION CRITERIA: We included randomised controlled trials which compared any neuromodulator to another therapy (active or placebo, including non-pharmacological therapies) in adult patients with RA that had at least one clinically relevant outcome measure. DATA COLLECTION AND ANALYSIS: Two blinded review authors independently extracted data and assessed the risk of bias in the trials. Meta-analyses were used to examine the efficacy of a neuromodulator on pain, depression and function as well as their safety. MAIN RESULTS: Four trials with high risk of bias were included in this review. Two trials evaluated oral nefopam (52 participants) and one trial each evaluated topical capsaicin (31 participants) and oromucosal cannabis (58 participants).The pooled analyses identified a significant reduction in pain levels favouring nefopam over placebo (weighted mean difference (WMD) -21.16, 95% CI -35.61 to -6.71; number needed to treat (NNT) 2, 95% CI 1.4 to 9.5) after two weeks. There were insufficient data to assess withdrawals due to adverse events. Nefopam was associated with significantly more adverse events (RR 4.11, 95% CI 1.58 to 10.69; NNTH 9, 95% CI 2 to 367), which were predominantly nausea and sweating.In a mixed population trial, qualitative analysis of patients with RA showed a significantly greater reduction in pain favouring topical capsaicin over placebo at one and two weeks (MD -23.80, 95% CI -44.81 to -2.79; NNT 3, 95% CI 2 to 47; MD -34.40, 95% CI -54.66 to -14.14; NNT 2, 95% CI 1.4 to 6 respectively). No separate safety data were available for patients with RA, however 44% of patients developed burning at the site of application and 2% withdrew because of this.One small, low quality trial assessed oromucosal cannabis against placebo and found a small, significant difference favouring cannabis in the verbal rating score 'pain at present' (MD -0.72, 95% CI -1.31 to -0.13) after five weeks. Patients receiving cannabis were significantly more likely to suffer an adverse event (risk ratio (RR) 1.82, 95% CI 1.10 to 3.00; NNTH 3, 95% CI 3 to 13). These were most commonly dizziness (26%), dry mouth (13%) and light headedness (10%). AUTHORS' CONCLUSIONS: There is currently weak evidence that oral nefopam, topical capsaicin and oromucosal cannabis are all superior to placebo in reducing pain in patients with RA. However, each agent is associated with a significant side effect profile. The confidence in our estimates is not strong given the difficulties with blinding, the small numbers of participants evaluated and the lack of adverse event data. In some patients, however, even a small degree of pain relief may be considered worthwhile. Until further research is available, given the relatively mild nature of the adverse events, capsaicin could be considered as an add-on therapy for patients with persistent local pain and inadequate response or intolerance to other treatments. Oral nefopam and oromucosal cannabis have more significant side effect profiles however and the potential harms seem to outweigh any modest benefit achieved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008921.pub2

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 61

  1. Deal, 1991, Treatment of arthritis with topical capsaicin: a double-blind trial, Clinical Therapeutics, 13, 383
  2. Emery, 1986, A double-blind study of the simple analgesic nefopam in rheumatoid arthritis, British Journal of Rheumatology, 25, 72, 10.1093/rheumatology/25.1.72 · doi:10.1093/rheumatology/25.1.72
  3. Swinson, 1988, Nefopam in rheumatoid arthritis. Results of a double-blind placebo controlled study, Clinical Rheumatology, 7, 411, 10.1007/BF02239203 · doi:10.1007/bf02239203
  4. Boon, 2010, Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study, PM and R, 2, 268, 10.1016/j.pmrj.2010.02.011 · DOI
  5. Dykstra, 2007, The effects of intra-articular botulinum toxin on sacroiliac, cervical/lumbar facet and sterno-clavicular joint pain and C-2 root and lumbar disc pain: a case series of 11 patients, The Pain Clinic, 19, 27–32, 10.1179/016911107X217473 · doi:10.1179/016911107x217473
  6. Hersh, 1994, Topical capsaicin-pharmacology and potential role in the treatment of temporomandibular pain, The Journal of Clinical Dentistry, 5, 54
  7. Singh, 2009, Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial, Translational Research, 153, 205, 10.1016/j.trsl.2009.02.004 · DOI
  8. Mahowald, 2009, Intra-articular botulinum toxin type A: A new approach to treat arthritis joint pain, Toxicon, 54, 658, 10.1016/j.toxicon.2009.03.028 · DOI
  9. McCarthy, 1992, Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands, Journal of Rheumatology, 19, 604–7
  10. Rao, 1995, Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study, Journal of Rheumatology, 22, 1235
  11. Richards, 1987, Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis, Annals of the Rheumatic Diseases, 46, 667, 10.1136/ard.46.9.667 · doi:10.1136/ard.46.9.667
  12. Singh, 2009, Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: A report of two cases, Joint, Bone, Spine, 76, 190, 10.1016/j.jbspin.2008.05.006 · doi:10.1016/j.jbspin.2008.05.006
  13. Mahowald, 2009, Intra-articular botulinum toxin A for refractory shoulder pain: a randomised, double-blinded, placebo-controlled trial, Toxicon, 153, 205
  14. Altman, 1994, Capsaicin cream, 0.025% as monotherapy for osteoarthritis: A double-blind study, Seminars in Arthritis and Rheumatism, 23, 25, 10.1016/S0049-0172(10)80023-X · doi:10.1016/s0049-0172(10)80023-x
  15. Bell, 2003, Ketamine as an adjuvant to opioids for cancer pain, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003351 · DOI
  16. Bell, 2006, Perioperative ketamine for acute postoperative pain, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004603.pub2 · DOI · Paper page
  17. Bendaly, 2007, Topiramate in the treatment of neuropathic pain in patients with cancer, Supportive Cancer Therapy, 4, 241, 10.3816/SCT.2007.n.021 · DOI
  18. Calignano, 1998, Control of pain initiation by endogenous cannabinoids, Nature, 394, 277–81, 10.1038/28393 · DOI · Paper page
  19. Cameron, 2011, Herbal therapy for treating rheumatoid arthritis, Cochrane database of systematic reviews (Online), 2, CD002948
  20. Campbell, 2001, Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review, BMJ, 323, 1–6, 10.1136/bmj.323.7303.13 · DOI · Paper page
  21. Chong, 2000, Anticonvulsants for the management of pain, Pain Reviews, 7, 129–49
  22. Cooper, 2003, What is pain management, and what is its relevance to the rheumatologist?, Rheumatology, 42, 1133, 10.1093/rheumatology/keg313 · DOI
  23. Davis, 2007, What is new in neuropathic pain?, Support Care Cancer, 15 (4), 363
  24. DeAngelis, 2004, Clinical trial registration: a statement from the International Committee of Medical Journal Editors, JAMA, 292, 1363, 10.1001/jama.292.11.1363 · DOI · Paper page
  25. Dworkin, 2007, Pharmacologic management of neuropathic pain: evidence-based recommendations, Pain, 132, 237–51, 10.1016/j.pain.2007.08.033 · DOI · Paper page
  26. Edwards, 2009, Enhanced reactivity to pain in patients with rheumatoid arthritis, Arthritis Research & Therapy, 11, R61, 10.1186/ar2684 · DOI
  27. Esposito, 1986, Evidence of the involvement of dopamine in the analgesic effect of nefopam, European Journal of Pharmacology, 128, 57, 10.1016/0014-2999(86)90762-4 · DOI
  28. Evans, 2008, Nefopam for the prevention of postoperative pain: quantitative systematic review, British Journal of Anaesthesia, 101, 610–7, 10.1093/bja/aen267 · DOI
  29. Finnerup, 2005, Algorithm for neuropathic pain treatment: an evidence based proposal, Pain, 118, 289–305, 10.1016/j.pain.2005.08.013 · DOI · Paper page
  30. Fisher, 2000, Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies,recent clinical experience and future research directions, Journal of Pain and Symptom Management, 20, 358–73, 10.1016/S0885-3924(00)00213-X · DOI · Paper page
  31. Franceschi, 1988, Fatal aplastic anemia in a patient treated with carbamazepine, Epilepsia, 29, 582, 10.1111/j.1528-1157.1988.tb03765.x · doi:10.1111/j.1528-1157.1988.tb03765.x
  32. Fries, 1980, Measurement of patient outcome in arthritis, Arthritis and Rheumatism, 23, 137, 10.1002/art.1780230202 · DOI · Paper page
  33. Fuller, 1993, Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice, Neuropharmacology, 32, 995, 10.1016/0028-3908(93)90064-A · DOI
  34. Gilron, 2006, Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence, Pain Research and Management, 11, 16, 10.1155/2006/651712 · DOI
  35. Heel, 1980, Nefopam: a review of its pharmacological properties and therapeutic efficacy, Drugs, 19, 249, 10.2165/00003495-198019040-00001 · doi:10.2165/00003495-198019040-00001
  36. Heiberg, 2002, Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority, Arthritis and Rheumatism, 47, 391, 10.1002/art.10515 · DOI · Paper page
  37. Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org
  38. Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org
  39. Hunskaar, 1987, Involvement of central serotonergic pathways in nefopam-induced anti-nociception, European Journal of Pharmacology, 138, 77, 10.1016/0014-2999(87)90339-6 · DOI
  40. Kakkar, 2009, Single dose oral nefopam for acute postoperative pain in adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007442.pub2 · DOI
  41. Mahowald, 2009, Repeat injections of intra-articular botulinum toxin A for the treatment of chronic arthritis joint pain – a case series review, Journal of Clinical Rheumatology, 15, 35–8
  42. Martín-Sánchez, 2009, Systematic review and meta-analysis of cannabis treatment for chronic pain, Pain Medicine, 10, 1353, 10.1111/j.1526-4637.2009.00703.x · DOI · Paper page
  43. Mason, 2004, Systematic review of topical capsaicin for the treatment of chronic pain, BMJ, 328, 991, 10.1136/bmj.38042.506748.EE · DOI · Paper page
  44. Morris, 1997, Characterisation of capsaicin-induced mechanical hyperalgesia as a marker for altered nociceptive processing in patients with rheumatoid arthritis, Pain, 71, 179, 10.1016/S0304-3959(97)03361-7 · DOI
  45. Nolano, 1999, Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation, Pain, 81, 135, 10.1016/S0304-3959(99)00007-X · DOI · Paper page
  46. Piercey, 1981, Spinal and supraspinal sites for morphine and nefopam analgesia in the mouse, European Journal of Pharmacology, 74, 135, 10.1016/0014-2999(81)90523-9 · DOI
  47. Pincus, 1983, Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire, Arthritis and Rheumatism, 26, 1346, 10.1002/art.1780261107 · DOI · Paper page
  48. Ranoux, 2008, Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain, Annals of Neurology, 64, 274–83, 10.1002/ana.21427 · DOI · Paper page
  49. Schünemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and ‘Summary of findings' tables In: Higgins JPT, Green S, editors, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org · DOI · Paper page
  50. Singh, 2009, Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: A report of two cases, Joint, Bone, Spine, 76, 190, 10.1016/j.jbspin.2008.05.006 · doi:10.1016/j.jbspin.2008.05.006
  51. Singh, 2011, Botulinum toxin for shoulder pain: a Cochrane systematic review, The Journal of Rheumatology, 38, 409, 10.3899/jrheum.101081 · DOI
  52. Skevington, 1998, Investigating the relationship between pain and discomfort and quality of life, using the WHOQOL, Pain, 76, 395, 10.1016/S0304-3959(98)00072-4 · DOI · Paper page
  53. Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention. Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org
  54. Tremont-Lukats, 2000, Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy, Drugs, 60, 1029, 10.2165/00003495-200060050-00005 · DOI · Paper page
  55. Walker, 2001, Cannabinoids and pain, Pain Research and Management, 6, 74–9, 10.1155/2001/413641 · DOI · Paper page
  56. Walker, 2005, Cannabinoid mechanisms of pain suppression, Handbook of Experimental Pharmacology, 168, 509–54
  57. Waseem, 2011, Botulinum toxin injections for low-back pain and sciatica, Cochrane Database of Systematic Reviews (Online), 1, CD008257
  58. Wiffen, 2005, Gabapentin for acute and chronic pain, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005452 · DOI · Paper page
  59. Wiffen, 2007, Lamotrigine for acute and chronic pain, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006044.pub2 · DOI
  60. Woolf, 1999, Neuropathic pain:aetiology, symptoms, mechanisms, and management, Lancet, 353, 1959–64, 10.1016/S0140-6736(99)01307-0 · DOI · Paper page
  61. Yuan, 2009, Botulinum toxin for diabetic neuropathic pain: a randomised double-blind crossover trial, Neurology, 72, 1473–8, 10.1212/01.wnl.0000345968.05959.cf · DOI · Paper page

Cited by

See all 100

Metadata

Authors
Richards, B. L., Whittle, S. L., & Buchbinder, R.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2012-01-18
Volume
2012
Issue
3
Pages
CD008921-CD008921
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2104535874
Cited by
100
References
7
FWCI
6.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuromodulators for pain management in rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/14651858.cd008921.pub2
The paper
Richards, B. L., Whittle, S. L., & Buchbinder, R. (2012). Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008921.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.